The estimated Net Worth of Jeff Evanson is at least $6.65 Million dollars as of 7 March 2024. Mr Evanson owns over 62,484 units of Outlook Therapeutics Inc stock worth over $5,683,467 and over the last 5 years he sold OTLK stock worth over $663,081. In addition, he makes $300,000 as Chief Commercial Officer at Outlook Therapeutics Inc.
Sign up
Mr Evanson OTLK stock SEC Form 4 insiders trading
Mr has made over 6 trades of the Outlook Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 62,484 units of OTLK stock worth $26,243 on 7 March 2024.
The largest trade he's ever made was selling 267,000 units of Outlook Therapeutics Inc stock on 20 January 2023 worth over $296,370. On average, Mr trades about 54,033 units every 102 days since 2020. As of 7 March 2024 he still owns at least 808,459 units of Outlook Therapeutics Inc stock.
You can see the complete history of Mr Evanson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Jeffrey Evanson biography
Jeffrey Evanson is the Chief Commercial Officer at Outlook Therapeutics Inc.
What is the salary of Mr Evanson?
As the Chief Commercial Officer of Outlook Therapeutics Inc, the total compensation of Mr Evanson at Outlook Therapeutics Inc is $300,000. There are 4 executives at Outlook Therapeutics Inc getting paid more, with Lawrence Kenyon having the highest compensation of $1,863,900.
How old is Mr Evanson?
Mr Evanson is 52, he's been the Chief Commercial Officer of Outlook Therapeutics Inc since . There are 10 older and 3 younger executives at Outlook Therapeutics Inc. The oldest executive at Outlook Therapeutics Inc is Ralph H. Thurman, 72, who is the Independent Exec. Chairman.
What's Mr Evanson's mailing address?
Jeff's mailing address filed with the SEC is C/O OUTLOOK THERAPEUTICS, INC., 485 ROUTE 1 SOUTH, BLDG F, SUITE 320, ISELIN, NJ, 08830.
Insiders trading at Outlook Therapeutics Inc
Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over $1,453,842 worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth $33,411,235 . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S..., Ghiath M.Gms Ventures & Inv..., and Ventures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of $11,985,869. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth $5,021,431.
What does Outlook Therapeutics Inc do?
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
What does Outlook Therapeutics Inc's logo look like?
Complete history of Mr Evanson stock trades at Outlook Therapeutics Inc
Outlook Therapeutics Inc executives and stock owners
Outlook Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Lawrence Kenyon,
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director -
Lawrence A. Kenyon CPA,
Exec. VP, CFO, Treasurer, Company Sec. & Director -
C. Russell Trenary III,
Pres, CEO & Director -
Randy Thurman,
Executive Chairman of the Board -
Terry Dagnon,
Chief Operations Officer -
Jeffrey Evanson,
Chief Commercial Officer -
Ralph H. Thurman,
Independent Exec. Chairman -
Jeremy Feffer,
IR Contact Officer -
Faisal Sukhtian,
Independent Director -
Kurt Hilzinger,
Independent Director -
Yezan Haddadin,
Independent Director -
Andong Huang,
Director -
Julian Gangolli,
Director -
Gerd Auffarth,
Director -
Jeff Evanson,
Chief Commercial Officer -
Terry Dagnon,
Chief Operating Officer -
Alicia Tozier,
Sr. VP, Marketing & Market Access -
Joel Prieve,
Sr. VP of Commercial Operations -
Elizabeth A. Yamashita,
Advisor -
Dr. Balu N. Balasubramanian,
Advisor -
Rick Gregory,
Director of Marketing & Communications -
C Russell Iii Trenary,
CEO AND PRESIDENT -
Pte Ltd.Pillai Arun Kumar S...,
-
Ghiath M.Gms Ventures & Inv...,
-
Joe Thomas,
Director -
Pte Ltd. Bio Lexis,
10% owner -
Faisal Ghiath Gms Ventures ...,
-
Arun Kumar Pillai,
Director -
Ventures Llc Syntone,
-
Julia A Haller,